Novel glucose-lowering drugs for non-alcoholic fatty liver disease

Table 2 Comparison of body weight and body mass index changes from baseline in different treatment groups

	Studies	Participants	WMD	95%CI		P value
Body weight change
DPP-4 inhibitors	4	140/138	-1.20	-1.44	-0.95	< 0.0001
GLP-1 RAs	8	1222/821	-3.61	-5.74	-1.48	0.0009
SGLT2 inhibitors	5	146/135	-2.53	-3.35	-1.71	< 0.0001
BMI change
DPP-4 inhibitors	5	144/146	-0.59	-1.80	0.61	0.33
GLP-1 RAs	7	251/293	-1.46	-2.23	-0.69	0.0002
SGLT2 inhibitors	4	114/101	-1.72	-2.68	-0.75	0.0005

WMD: Weighted mean difference; CI: Confidence interval; DPP-4: Dipeptidyl peptidase-4; GLP-1 RA: Glucagon-like peptide-1 receptor agonist; SGLT2: Sodium-glucose cotransporter 2; BMI: Body mass index.